Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2022-02-18

Clinical Trial Update: A Study of Etoricoxib in Participants With Osteoarthritis Not Responding to Analgesic Drugs (MK-0663-142) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial of etoricoxib in osteoarthritis participants not responding to analgesics was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Etoricoxib (etoricoxib)

Snippet

Sponsor: Organon and Co | Conditions: Osteoarthritis | Phase 4 | Status: WITHDRAWN